Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S093000
Reexamination Certificate
active
10989514
ABSTRACT:
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
REFERENCES:
patent: 3326924 (1967-06-01), Villani
patent: 3391143 (1968-07-01), Kaiser et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4282233 (1981-08-01), Villani
patent: 4659716 (1987-04-01), Villani et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5714501 (1998-02-01), Timmerman et al.
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 6051585 (2000-04-01), Weinstein et al.
patent: 0 288 640 (1988-11-01), None
patent: 0 780 127 (1997-06-01), None
patent: W O 85/03707 (1985-08-01), None
patent: WO85/03707 (1985-08-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 92/11034 (1992-07-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 96/20708 (1996-07-01), None
patent: WO 97/28797 (1997-08-01), None
patent: WO 99/32125 (1999-07-01), None
Berkow et al. (I, eds.), The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck Research Laboratories, Rahway, NJ, May, 1992, only pp. 332-334 supplied.
Gennaro et al. (eds.), Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA, 1990, only pp. 678 and 1123-1124 (from Chs. 34 & 59, respectively) are supplied.
Thomas et al. (eds.), Taber's Cyclopedic Medical Dictionary, 17th Illustrated Edition, F. A. Davis Company, Philadelphia, PA, 1993, only pp. 2091-2092 supplied.
Bocian, R, “Hay Fever (Allergic Rhinitis): Current Management Approaches,” Palo Alto Medical Foundation, Spring, 2000, see <http://www.pamf.org/health/toyourhealth/hayfever/html>.
E. W. Monroe, “Loratadine in the Treatment of Urticaria,” Clinical Therapeutics, 19(2), 232-242 (1997).
Knowles et al., “Astemizole and Terfenadine-Induces Cardiovascular Effects,” Canadian Journal of Hospital Pharmacy, 45(1), 33 & 37 (Feb., 1992).
Isselbacher et al. (eds.), Harrison's Principles of Internal Medicine, Thirteenth Edition, McGraw-Hill, Inc., New York, NY, 1994, only pp. 402-403 supplied.
Estelle et al., “The Pharmacology and Use of H1-Receptor-Antagonist Drugs,” The New England Journal of Medicine, 330(23), 1665-1670 (Jun. 9, 1994).
Berkow et al. (II, eds.), The Merck Manual of Diagnosis and Therapy, Sixteenth Edition, Merck & Co., Rahway, NJ, May, 1992, only pp. 1262-1265 provided.
Brandes et al. (I), “Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H1-Antihistamines: Predictive . . . ,” PubMed (National Library of Medicine USA): PMID 7909571, published on line in 1994: only Abstract supplied.
E. A. Swinyard (I), “Gastrointestinal Drugs,” Chapter 39 in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 774-799 supplied.
E. A. Swinyard (II), “Histamine and Antihistamines,” Chapter 59 in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pp. 1123-1131 supplied.
Brandes et al. (II), “Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H1-Antihistamines: Predictive in vitro Correlates,” Journal of the National Cancer Institute, 86(10), 770-775 (May 18, 1994).
S. L. Nightingale, Warning Issued on Nonsedating Antihistamines Terfenadine and Astemizole, Journal of the American Medical Association, 268(6), 705 (Aug. 12, 1992).
Berthon et al., “In Vitro Inhibition, by Loratadine and Descarbethoxy-loratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in . . . ,” Biochemical Pharmacology, 47(5), 789-794 (1994).
J. F. Wiley II, et al., “Cardiotoxic Effects of Astemizole Overdose in Children,” Journal of Pediatrics, 120(5), 799-802 (May, 1992).
A. Van Peer et al., “Ketoconazole Inhibits Loratadine Metabolism in Man,” European Journal of Allergy & Clinical Immunology, 48(Suppl. 16), 34, 1993: Derwent Abstract Accession No.: 93-55671; only abstract supplied.
C.I. Ezeamuzie et al., “Effect of Histamine H2-Receptor Antagonists on Acute Inflammatory of the Rat Paw Oedema,” J. Pharm. Pharmacol., 41, 261-265 (1989).
K. Kyuki et al., “Topical Anti-Inflammatory Activity of Dexamethasone 17-Valerate,” Nippon Yakurigaku Zasshi, 77(1), 73-85 (Jan., 1981).
S. Kawaguchi et al., “Nasal Mast Cell in Experimentally Induced Allergic Rhinitis in Guinea-Pigs,” Clinical and Experimental Allergy, 24, 238-244 (1994).
T. Abe et al., “Antiallergic Effects of ZCR-2060: Effect on Allergic Cutaneous Reactions and Rhinitis Models in Mice and Rats,” Japanese Journal of Pharmacology, 66, 95-103 (1994).
A. G. Gilman et al. (I, eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition, Pergamon Press, New York, NY, 1990, only pp. 7, 197-199 and 582-588 supplied.
A. G. Gilman et al. (II, eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Pergamon Press, New York, NY, 1996, only p. 588 supplied.
A. P. Good et al., “Loratadine and Ventricular Tachycardia,” Journal of Cardiology, 74(15), 207 (1994).
K. Nyman et al., “Serious Side Effects of the Antiallergic Loratadine—Warning Against Long-Term Use of Non-Prescription Preparation,” Lakartidningen, 99(25), 2281 (1992); only English translation provided.
R. W. Brimblecomb et al., “The Pharmacology of Burimamide and Metiamide, Two Histamine H2 Receptor Antagonists,” Federation Proceedings, 35(8), 1931-1934 (Jun., 1976).
N. Takahashi et al., “Allergic Rhinitis Model with Brown Norway Rat and Evaluation of Antiallergic Drugs,” Journal Pharmacobio-Dyn., 13, 414-420 (1990).
Merck Index, 12th Edition, Merck & Co., Rahway, NJ, 1990, only pp. 132, 892, 5611 and 9307 supplied.
H. G. Mandel, “Pathways of Drug Biotransformation: Biochemical Conjugates,” Chaper 10 in Fundamentals of Drug Metabolism and Drug Disposition, Williams & Wilkins, Baltimore, MD, 1971, only pp. 149-151 supplied.
R. L. Woolsey et al., “Effects of Astemizole and Its Metabolites on Cardiac Repolarization,” Georgetown University Document No. AST-2, Georgetown University, Washington, D.C., 1995; See also Sepracor Document No. 110-408.
R. Arky et al. (eds.), Physician's Desk Reference, 1994 Edition, Medical Economics Data Production Company, Montvale, NJ, only pp. 1087-1090 supplied.
A. G. Gilman et al. (III, eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Pergamon Press, New York, NY, 1996, only p. 590 supplied.
EPO Oral Proceeding, written record of Refusal of an EP Patent Application for EP Application No. 95 943 722.9-2112, Sep. 8, 2000, see entire document.
Notari et al. “Biopharmaceutics and pharmacokinetics” Marcel Dekker, p. 163-164 (1975).
Quercia et al. “Focus on loratadine: . . . ” CA 118:247148 (1993).
hilbert et al. “Pharmacokinetics and dose proportionality of loratadine” CA 108:31237 (1988).
Garattini “Active drug metabolites . . . ” Clin. Pharm. 10:216-227 (1985).
Sepracor “Fact sheet” 2006, p. 1-4 (copy in copending U.S. Appl. No. 09/447,218).
Babe et al., 1996, “Histamine, Bradykinin, and Their Antagonists”,Goodman&Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 581-593 and 598-599.
McCue, J., 1996, “Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients”, Arch. Fam. Med. 5:464-468.
Andersen et al.,
Aberg A. K. Gunnar
McCullough John R.
Smith Emil R.
Chang Celia
Jones Day
Sepracor Inc.
LandOfFree
Methods for the treatment of allergic rhinitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of allergic rhinitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of allergic rhinitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3817672